CN104957714A - Compound American ginseng essential oil drink to prevent neuronal damage in elderly - Google Patents
Compound American ginseng essential oil drink to prevent neuronal damage in elderly Download PDFInfo
- Publication number
- CN104957714A CN104957714A CN201510293941.3A CN201510293941A CN104957714A CN 104957714 A CN104957714 A CN 104957714A CN 201510293941 A CN201510293941 A CN 201510293941A CN 104957714 A CN104957714 A CN 104957714A
- Authority
- CN
- China
- Prior art keywords
- american ginseng
- essential oil
- oil
- ginseng essential
- drink
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000003140 Panax quinquefolius Nutrition 0.000 title claims abstract description 53
- 240000005373 Panax quinquefolius Species 0.000 title claims abstract description 50
- 239000000341 volatile oil Substances 0.000 title claims abstract description 46
- 150000001875 compounds Chemical class 0.000 title claims abstract description 24
- 230000003961 neuronal insult Effects 0.000 title abstract 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 60
- 235000019498 Walnut oil Nutrition 0.000 claims abstract description 22
- 239000008170 walnut oil Substances 0.000 claims abstract description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 22
- 239000000178 monomer Substances 0.000 claims abstract description 21
- 230000001954 sterilising effect Effects 0.000 claims abstract description 21
- 235000012907 honey Nutrition 0.000 claims abstract description 20
- 239000000839 emulsion Substances 0.000 claims abstract description 10
- 238000004659 sterilization and disinfection Methods 0.000 claims abstract description 10
- 238000002360 preparation method Methods 0.000 claims abstract description 7
- 238000004945 emulsification Methods 0.000 claims abstract description 6
- 238000002156 mixing Methods 0.000 claims abstract description 5
- 239000000203 mixture Substances 0.000 claims abstract description 5
- 239000003921 oil Substances 0.000 claims description 19
- 235000019198 oils Nutrition 0.000 claims description 19
- 229940089161 ginsenoside Drugs 0.000 claims description 18
- 229930182494 ginsenoside Natural products 0.000 claims description 18
- 210000002569 neuron Anatomy 0.000 claims description 18
- 230000009758 senescence Effects 0.000 claims description 18
- 230000002490 cerebral effect Effects 0.000 claims description 16
- 208000014674 injury Diseases 0.000 claims description 16
- 230000008733 trauma Effects 0.000 claims description 16
- 230000002265 prevention Effects 0.000 claims description 15
- 238000001816 cooling Methods 0.000 claims description 4
- 230000000694 effects Effects 0.000 abstract description 6
- 238000000034 method Methods 0.000 abstract description 6
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 abstract description 5
- 235000008434 ginseng Nutrition 0.000 abstract description 5
- 230000003449 preventive effect Effects 0.000 abstract description 2
- 241000208340 Araliaceae Species 0.000 abstract 3
- 235000019496 Pine nut oil Nutrition 0.000 abstract 3
- 239000010490 pine nut oil Substances 0.000 abstract 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 abstract 3
- 229930182490 saponin Natural products 0.000 abstract 3
- 150000007949 saponins Chemical class 0.000 abstract 3
- 238000000265 homogenisation Methods 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 description 7
- 238000000746 purification Methods 0.000 description 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- UGJAEDFOKNAMQD-DVQDXYAYSA-N (-)-Falcarinol Natural products CCCCCCC\C=C\CC#CC#C[C@@H](O)C=C UGJAEDFOKNAMQD-DVQDXYAYSA-N 0.000 description 3
- UGJAEDFOKNAMQD-MQNTZWLQSA-N (3S,9Z)-1,9-Heptadecadiene-4,6-diyn-3-ol Chemical compound CCCCCCC\C=C/CC#CC#C[C@@H](O)C=C UGJAEDFOKNAMQD-MQNTZWLQSA-N 0.000 description 3
- UGJAEDFOKNAMQD-UHFFFAOYSA-N Falcarinol Natural products CCCCCCCC=CCC#CC#CC(O)C=C UGJAEDFOKNAMQD-UHFFFAOYSA-N 0.000 description 3
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 235000020778 linoleic acid Nutrition 0.000 description 3
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 3
- KKAHGGJBKUXDNQ-KRWDZBQOSA-N panaxynol Natural products CCCCCCCC=CC=CCC#C[C@@H](O)C=C KKAHGGJBKUXDNQ-KRWDZBQOSA-N 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 235000002791 Panax Nutrition 0.000 description 2
- 241000208343 Panax Species 0.000 description 2
- GVLDSGIQZAFIAN-UHFFFAOYSA-N Panaxydol Natural products CCCCCCCC1OC1CC#CC#CC(O)C=C GVLDSGIQZAFIAN-UHFFFAOYSA-N 0.000 description 2
- 206010039966 Senile dementia Diseases 0.000 description 2
- 150000001345 alkine derivatives Chemical class 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical group NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- GVLDSGIQZAFIAN-IXDOHACOSA-N panaxydol Chemical compound CCCCCCC[C@@H]1O[C@@H]1CC#CC#C[C@H](O)C=C GVLDSGIQZAFIAN-IXDOHACOSA-N 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- HPOIPOPJGBKXIR-UHFFFAOYSA-N 3,6-dimethoxy-10-methyl-galantham-1-ene Natural products O1C(C(=CC=2)OC)=C3C=2CN(C)CCC23C1CC(OC)C=C2 HPOIPOPJGBKXIR-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- LPCKPBWOSNVCEL-UHFFFAOYSA-N Chlidanthine Natural products O1C(C(=CC=2)O)=C3C=2CN(C)CCC23C1CC(OC)C=C2 LPCKPBWOSNVCEL-UHFFFAOYSA-N 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 102000001490 Opioid Peptides Human genes 0.000 description 1
- 108010093625 Opioid Peptides Proteins 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 230000000648 anti-parkinson Effects 0.000 description 1
- 239000000939 antiparkinson agent Substances 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 210000003618 cortical neuron Anatomy 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 229960003980 galantamine Drugs 0.000 description 1
- BGLNUNCBNALFOZ-WMLDXEAASA-N galanthamine Natural products COc1ccc2CCCC[C@@]34C=CCC[C@@H]3Oc1c24 BGLNUNCBNALFOZ-WMLDXEAASA-N 0.000 description 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 1
- -1 how how croak Chemical compound 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- IYVSXSLYJLAZAT-NOLJZWGESA-N lycoramine Natural products CN1CC[C@@]23CC[C@H](O)C[C@@H]2Oc4cccc(C1)c34 IYVSXSLYJLAZAT-NOLJZWGESA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000019581 neuron apoptotic process Effects 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 239000003399 opiate peptide Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229960001685 tacrine Drugs 0.000 description 1
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The present invention discloses a compound American ginseng essential oil drink to prevent neuronal damage in elderly and the American ginseng essential oil drink consists of the following components: American ginseng essential oil, walnut oil, pine nut oil, ginseng saponin monomer Re, citric acid, honey and pure water; and the mass ratio of all the components is as follows : American ginseng essential oil : walnut oil : pine nut oil : ginseng saponin monomer Re : citric acid : honey : pure water = 1 : 0.5-0.7 : 0.5-0.7 : 0.01-0.03 : 0.01-0.03 : 0.24-0.44 : 15.4-19.4. The preparation steps are as follows: the American ginseng essential oil, walnut oil, pine nut oil, ginseng saponin monomer Re, citric acid, honey and pure water at the above mass ratio are poured into a mixing tank to be mixed, and then the mixture is moved into a homogenizer to be subjected to emulsification so as to form an emulsion at a homogenization pressure of 40-50 Mpa; and the emulsion is poured into a high temperature resistant flask, placed in an autoclave for sterilization at a sterilization temperature of 110-120 DEG C for a sterilization time of 15-25 minutes, and then naturally cooled to obtain the compound American ginseng essential oil drink. The process is simple and convenient, and the compound American ginseng essential oil drink has no toxic or side effects and has a good preventive effect.
Description
Technical field
The present invention relates to a kind of drink, particularly a kind of compound American Ginseng essential oil drink preventing senescence phase trauma of cerebral nerve cell, belongs to the elderly's field of health care products.
Background technology
Increasing along with social senilization's population, the senescence phase, brain neuron DD crowd also increased year by year, and the healthy of the elderly and quality of life in serious harm.Medicine is mainly utilized to treat senescence phase brain neuron DD at present, as neat in Tacrine, how how croak, galanthamine etc.These medicines can only play mitigation to a certain extent, and result for the treatment of is also not obvious, has obvious side effect simultaneously.In prevention, corresponding medicine or health products are not selected for the elderly.
Summary of the invention
The object of this invention is to provide a kind of easy to process, processing ease, simple process, have no side effect, the compound American Ginseng essential oil drink of prevention senescence phase trauma of cerebral nerve cell that preventive effect is good and preparation method thereof, overcome the deficiencies in the prior art.
The compound American Ginseng essential oil drink of prevention senescence phase trauma of cerebral nerve cell of the present invention, is made up of following component: American Ginseng essential oil, walnut oil, pine-seed oil, ginsenoside monomer Re, citric acid, honey, pure water;
The quality proportioning of each component is as follows:
American Ginseng essential oil: walnut oil: pine-seed oil: ginsenoside monomer Re: citric acid: honey: pure water=1: 0.5 ~ 0.7: 0.5 ~ 0.7: 0.01 ~ 0.03: 0.01 ~ 0.03: 0.24 ~ 0.44: 15.4 ~ 19.4.
The compound American Ginseng essential oil drink of prevention senescence phase trauma of cerebral nerve cell of the present invention, the quality proportioning of each component can be:
American Ginseng essential oil: walnut oil: pine-seed oil: ginsenoside monomer Re: citric acid: honey: pure water=1: 0.6: 0.6: 0.02: 0.02: 0.34: 17.4.
The preparation method of the compound American Ginseng essential oil drink of prevention senescence phase trauma of cerebral nerve cell of the present invention, step is as follows:
By American Ginseng essential oil, walnut oil, pine-seed oil, ginsenoside monomer Re, citric acid, honey, pure water by 1: 0.5 ~ 0.7: 0.5 ~ 0.7: 0.01 ~ 0.03: 0.01 ~ 0.03: 0.24 ~ 0.44: 15.4 ~ 19.4 quality proportioning, or press the quality proportioning of 1: 0.6: 0.6: 0.02: 0.02: 0.34: 17.4, pour in agitator tank and mix, emulsification in homogenizer is moved into again after mixing, form emulsion, during homogeneous, pressure is 40 ~ 50Mpa; Poured in high temperature resistant bottle by emulsion, put into autoclave and carry out sterilizing, sterilising temp 110 ~ 120 DEG C, sterilization time 15 ~ 25 minutes, then cooling can obtain compound American Ginseng essential oil drink naturally.
The preparation method of compound American Ginseng essential oil drink of prevention senescence phase trauma of cerebral nerve cell of the present invention, during wherein said homogeneous, pressure is 45Mpa; High temperature resistant bottle capacity is at least 200ml; Sterilising temp is 115 DEG C; Sterilization time is 20 minutes.
The compound American Ginseng essential oil drink mouthfeel of prevention senescence phase trauma of cerebral nerve cell of the present invention is good, be easy to take, senescence phase trauma of cerebral nerve cell can be prevented for a long time for tea-drinking, avoid the generation of senile dementia and have no side effect, fill up the blank of prevention senescence phase trauma of cerebral nerve cell health beverages, improve the quality of life of the elderly.
Panaxynol > 40%, panaxydol > 30% in this drink American Ginseng essential oil.Panaxynol is the important activity composition of neurotrophy and neuroprotection.Panaxynol and panaxydol have protective effect to A β 25-35 damaged brain cortical neuron.Walnut oil has brain tonic to support the effect of brain, not containing cholesterol in walnut oil, effectively can prevent the generation of senile dementia; Abundant linoleic acid plus linolenic acid can get rid of the metabolic impurity of Ink vessel transfusing, makes blood purification, for brain provides new blood.Pine-seed oil can reduce cholesterol and triglycerides, plays an important role in pine-seed oil containing a large amount of vitamin Es to treatment and prevention cardiovascular and cerebrovascular disease.Patent CN1650876 discloses a kind of novelty teabag of panax saponin-Re anti-parkinson; propose panax saponin-Re to 1-methyl 4-phenyl-1; 2; 3; 6-tetrahydropyridine causes parkinsonian mouse and has protective effect, at protection dopamine form and function, suppression black substance proliferation of astrocytes, regulates the several respects such as brain endogenous opioid peptides and anti-substantia nigra neuron apoptosis all to have effect.Above material combination uses, and health-care effect is remarkable.
Method of the present invention is easy to process, processing ease, and technique is simple.
Detailed description of the invention
The compound American Ginseng essential oil drink of prevention senescence phase trauma of cerebral nerve cell of the present invention, is made up of following component: American Ginseng essential oil, walnut oil, pine-seed oil, ginsenoside monomer Re, citric acid, honey, pure water;
The quality proportioning of each component is as follows:
American Ginseng essential oil: walnut oil: pine-seed oil: ginsenoside monomer Re: citric acid: honey: pure water=1: 0.5 ~ 0.7: 0.5 ~ 0.7: 0.01 ~ 0.03: 0.01 ~ 0.03: 0.24 ~ 0.44: 15.4 ~ 19.4, in above-mentioned ratio interval.
The quality proportioning of each component is preferably as follows:
American Ginseng essential oil: walnut oil: pine-seed oil: ginsenoside monomer Re: citric acid: honey: pure water=1: 0.6: 0.6: 0.02: 0.02: 0.34: 17.4.
The preparation method of the compound American Ginseng essential oil drink of prevention senescence phase trauma of cerebral nerve cell of the present invention, step is as follows:
By American Ginseng essential oil, walnut oil, pine-seed oil, ginsenoside monomer Re, citric acid, honey, pure water by 1: 0.5 ~ 0.7: 0.5 ~ 0.7: 0.01 ~ 0.03: 0.01 ~ 0.03: 0.24 ~ 0.44: 15.4 ~ 19.4 quality proportioning, or press the quality proportioning of 1: 0.6: 0.6: 0.02: 0.02: 0.34: 17.4, pour in agitator tank and mix, emulsification in homogenizer is moved into again after mixing, form emulsion, during homogeneous, pressure is 40 ~ 50Mpa; Poured in high temperature resistant bottle by emulsion, put into autoclave and carry out sterilizing, sterilising temp 110 ~ 120 DEG C, sterilization time 15 ~ 25 minutes, then cooling can obtain compound American Ginseng essential oil drink naturally.During homogeneous, pressure is preferably 45Mpa; High temperature resistant bottle capacity is at least 200ml; Sterilising temp is preferably 115 DEG C; Sterilization time is preferably 20 minutes.
Instantiation:
One, raw material:
1. American Ginseng essential oil can select the product of Dalian right way bioengineering Co., Ltd, the key technical indexes: ginseng alkynes 41%, ginseng epoxy alkynes 35%, brown glutinous shape liquid, have the peculiar fragrance of American Ginseng.Acid number 0.9mg KOH/g.
2. ginsenoside monomer Re selects the product of large adhesion Sheng Lvgu bioengineering Co., Ltd, the key technical indexes: ginsenoside monomer Re content 97.2%.
3. the product of Dalian right way bioengineering Co., Ltd selected by walnut oil, the key technical indexes: linoleic acid 65.2%, leukotrienes 10.1%, acid number 0.64mg KOH/g.
4. pine-seed oil selects the product of Jilin Painuo Biological Technology Co., Ltd., the key technical indexes: linoleic acid 57.3%, acid number 0.38mg KOH/g.
5, pure water can select Wahaha brand big barrel water or other pure water.
6, honey and citric acid can select the product that market is sold.
Equipment: homogenizer can select the product of Langfang General Machinery Co. Ltd., autoclave can select the product of Hefei Hua Tai Medical Devices Co., Ltd.
Two, prepare: 0.5 kilogram of American Ginseng essential oil, 0.3 kilogram of walnut oil, 0.3 kilogram of pine-seed oil, 0.01 kilogram of ginsenoside monomer Re, 0.01 kilogram of citric acid, 0.17 kilogram of honey, 8.7 kg of pure water purification, above 7 kinds of raw materials are poured in agitator tank and mixes, emulsification in homogenizer is squeezed into again after mixing, form emulsion, during emulsification, Stress control is 45Mpa or 40Mpa or 50Mpa.Then poured into by emulsion in high temperature resistant bottle, every bottle of 200ml, put into autoclave and carry out sterilizing, sterilising temp is 115.DEG C or 110 DEG C or 120 DEG C, sterilization time is 20 minutes or 15 minutes or 25 minutes.Naturally after cooling.
Above-mentioned each component can also be selected as follows: 1 kilogram of American Ginseng essential oil, 0.5 kilogram of walnut oil, 0.5 kilogram of pine-seed oil, 0.01 kilogram of ginsenoside monomer Re, 0.01 kilogram of citric acid, 0.24 kilogram of honey, 15.4 kg of pure water purification; Or 1 kilogram of American Ginseng essential oil, 0.7 kilogram of walnut oil, 0.7 kilogram of pine-seed oil, 0.03 kilogram of ginsenoside monomer Re, 0.03 kilogram of citric acid, 0.44 kilogram of honey, 19.4 kg of pure water purification; Or 1 kilogram of American Ginseng essential oil, 0.6 kilogram of walnut oil, 0.7 kilogram of pine-seed oil, 0.01 kilogram of ginsenoside monomer Re, 0.02 kilogram of citric acid, 0.30 kilogram of honey, 18 kg of pure water purification.Namely in the above-mentioned numerical intervals provided.
Li Xiangfeng, female, 80 years old, ID card No. 220621193611080046, retirement 30 years, starts to take compound American Ginseng essential oil drink of the present invention, every day 2 bottles (200ml dress) for 2014 every day, so far do not occur forgetful, depressed, have a dull expression on one's face, the symptom such as rule of sleeping is disorderly, the state of mind is very good.
Take the investigation of compound American Ginseng essential oil drink crowd of the present invention:
Claims (4)
1. prevent a compound American Ginseng essential oil drink for senescence phase trauma of cerebral nerve cell, it is characterized in that: described compound American Ginseng essential oil drink is made up of following component: American Ginseng essential oil, walnut oil, pine-seed oil, ginsenoside monomer Re, citric acid, honey, pure water;
The quality proportioning of each component is as follows:
American Ginseng essential oil: walnut oil: pine-seed oil: ginsenoside monomer Re: citric acid: honey: pure water=1: 0.5 ~ 0.7: 0.5 ~ 0.7: 0.01 ~ 0.03: 0.01 ~ 0.03: 0.24 ~ 0.44: 15.4 ~ 19.4.
2. the compound American Ginseng essential oil drink of prevention senescence phase trauma of cerebral nerve cell according to claim 1, is characterized in that: the quality proportioning of described each component is as follows:
American Ginseng essential oil: walnut oil: pine-seed oil: ginsenoside monomer Re: citric acid: honey: pure water=1: 0.6: 0.6: 0.02: 0.02: 0.34: 17.4.
3. a preparation method for the compound American Ginseng essential oil drink of prevention senescence phase trauma of cerebral nerve cell according to claim 1, is characterized in that: step is as follows:
By American Ginseng essential oil, walnut oil, pine-seed oil, ginsenoside monomer Re, citric acid, honey, pure water by 1: 0.5 ~ 0.7: 0.5 ~ 0.7: 0.01 ~ 0.03: 0.01 ~ 0.03: 0.24 ~ 0.44: 15.4 ~ 19.4 quality proportioning, or press the quality proportioning of 1: 0.6: 0.6: 0.02: 0.02: 0.34: 17.4, pour in agitator tank and mix, emulsification in homogenizer is moved into again after mixing, form emulsion, during homogeneous, pressure is 40 ~ 50Mpa; Poured in high temperature resistant bottle by emulsion, put into autoclave and carry out sterilizing, sterilising temp 110 ~ 120 DEG C, sterilization time 15 ~ 25 minutes, then cooling can obtain compound American Ginseng essential oil drink naturally.
4. the preparation method of compound American Ginseng essential oil drink of prevention senescence phase trauma of cerebral nerve cell according to claim 3, is characterized in that: during described homogeneous, pressure is 45Mpa; High temperature resistant bottle capacity is at least 200ml; Sterilising temp is 115 DEG C; Sterilization time is 20 minutes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510293941.3A CN104957714A (en) | 2015-05-26 | 2015-05-26 | Compound American ginseng essential oil drink to prevent neuronal damage in elderly |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510293941.3A CN104957714A (en) | 2015-05-26 | 2015-05-26 | Compound American ginseng essential oil drink to prevent neuronal damage in elderly |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104957714A true CN104957714A (en) | 2015-10-07 |
Family
ID=54211946
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510293941.3A Pending CN104957714A (en) | 2015-05-26 | 2015-05-26 | Compound American ginseng essential oil drink to prevent neuronal damage in elderly |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104957714A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030077313A1 (en) * | 2000-10-17 | 2003-04-24 | Robert Schwartz | Anti-stress composition intended for incorporation mainly in nutritional vehicles |
| CN1650876A (en) * | 2004-02-06 | 2005-08-10 | 徐琲琲 | New use of ginseng saponin-Re medicine and its preparation method |
| CN101134058A (en) * | 2007-09-29 | 2008-03-05 | 王玉良 | Health products having blood fat and blood pressure reducing functions and manufacturing method thereof |
| CN101312650A (en) * | 2005-09-19 | 2008-11-26 | 草药科学新加坡私人有限公司 | Compositions and methods comprising panax species |
| CN103110102A (en) * | 2013-02-20 | 2013-05-22 | 许伯宗 | Health-care product for supplying brain nutrition |
| CN103271960A (en) * | 2013-06-20 | 2013-09-04 | 敦化市广晟油脂生物科技有限责任公司 | Preparation method of ginseng cream richly containing scare ginsenosides Rg3 and Rh2 |
-
2015
- 2015-05-26 CN CN201510293941.3A patent/CN104957714A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030077313A1 (en) * | 2000-10-17 | 2003-04-24 | Robert Schwartz | Anti-stress composition intended for incorporation mainly in nutritional vehicles |
| CN1650876A (en) * | 2004-02-06 | 2005-08-10 | 徐琲琲 | New use of ginseng saponin-Re medicine and its preparation method |
| CN101312650A (en) * | 2005-09-19 | 2008-11-26 | 草药科学新加坡私人有限公司 | Compositions and methods comprising panax species |
| CN101134058A (en) * | 2007-09-29 | 2008-03-05 | 王玉良 | Health products having blood fat and blood pressure reducing functions and manufacturing method thereof |
| CN103110102A (en) * | 2013-02-20 | 2013-05-22 | 许伯宗 | Health-care product for supplying brain nutrition |
| CN103271960A (en) * | 2013-06-20 | 2013-09-04 | 敦化市广晟油脂生物科技有限责任公司 | Preparation method of ginseng cream richly containing scare ginsenosides Rg3 and Rh2 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102697127B (en) | The preparation method of sweet-corn beverage | |
| CN106376796A (en) | Health-care fruit and vegetable beverage and preparation method thereof | |
| CN104171774A (en) | Enzymolysis flavored golden pomelo paste and production method thereof | |
| CN103815494A (en) | Heat-clearing alcoholism-relieving carambola composite beverage and preparation method thereof | |
| CN1875787A (en) | Health tea drink of Aizoon stonecrop herb | |
| CN102845748B (en) | Composition containing tea polyphenol and cordyceps militaris and preparation method thereof | |
| CN104382031B (en) | A kind of Ms's nutrient solution and preparation method thereof | |
| CN106107289A (en) | A kind of blue berry fruit juice beverage | |
| KR101435930B1 (en) | Method for production of red ginseng extract enhancing ginsenoside Ｒｇ３ and use of thereof as ginsenoside Ｒｇ３ enriched products | |
| CN104962392A (en) | Preparation method of chamomile extracts, healthcare milk beverage with chamomile extracts and processing method of milk beverage | |
| CN101884408B (en) | Ginkgo leaf leaching liquor and preparation method thereof | |
| CN104212694A (en) | Sunstroke-preventing fruit vinegar and preparation method thereof | |
| CN103330247A (en) | Selenium-enriched medlar drink | |
| CN105661195A (en) | Blueberry beverage and preparation method thereof | |
| CN104957714A (en) | Compound American ginseng essential oil drink to prevent neuronal damage in elderly | |
| CN108142766A (en) | A kind of dendrobium candidum beverage and preparation method thereof | |
| CN103371246A (en) | Healthcare green tea, apple and liquorice compound beverage | |
| CN102302104A (en) | Lycopene bee pollen and making method thereof | |
| CN107582689A (en) | A kind of quick Anti-alcoholism Chinese medicinal composition | |
| CN104031811A (en) | Citrus siraitia grosvenorii wine preparation method | |
| CN109287909B (en) | Momordica grosvenori plant functional beverage and preparation method thereof | |
| CN106581414A (en) | Hippophae rhamnoides leaf five-component pill with effects of blood fat regulating, lipoprotein (a) lowering and blood viscosity lowering, and preparation method thereof | |
| CN102640918A (en) | Preparation method of ant, burdock and ganoderma lucidum liquid | |
| CN103877529A (en) | Formula and production process for medicinal liquor used for treating rheumatism | |
| CN104473282A (en) | Ginger and vinegar beverage and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20151007 |